This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Mouse model for nonalcoholic fatty liver disease	<p>A mouse model of nonalcoholic fatty liver disease (NAFLD) could be used to help identify therapeutics. The I148M variant of <i>patatin-like phospholipase domain containing 3</i> (<i>PNPLA3</i>; <i>ADPN</i>) is a risk factor for NAFLD. Mice that overexpressed the I148M variant of human <i>PNPLA3</i> in the liver had a fatty liver phenotype and showed other metabolic features of NAFLD. In these mice, liver secretions showed less hydrolysis and higher levels of disease-causing triacylglycerol than liver secretions from wild-type controls. Next steps could include using the model to evaluate therapeutic candidates.</p> <p>SciBX 5(41); doi:10.1038/scibx.2012.1093 Published online Oct. 18, 2012</p>	Patent and licensing status unavailable	<p>Li, J.Z. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Oct. 1, 2012; doi:10.1172/JCI65179 Contact: Helen H. Hobbs, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: helen.hobbs@utsouthwestern.edu</p>